Japan Zolbetuximab Filing Heats Up CLDN18.2 Competition

US, EU, China Filings Also Expected

 
• By Lisa Takagi
  
As Zolbetuximab reaches for approval, it awaits fierce competition for CLDN18.2-targeting drugs.
With first filing, zolbetuximab appears to be leading leading fierce global competition for CLDN18.2-targeting drugs. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category